Neuronetics, Inc. has announced its financial results for the third quarter of 2026, showcasing a significant turnaround in its performance. The company reported a 12.5% increase in total revenue year-over-year, reaching $42.0 million. This growth is particularly notable as it comes amidst a competitive landscape in the surgical and medical instruments industry.

For the three and nine months ended September 30, 2026, Neuronetics highlighted key financial metrics that underscore its recovery and growth trajectory. The company’s revenue from its Greenbrook network surged by 20.1% year-over-year, amounting to $26.2 million. This network is integral to Neuronetics’ strategy, providing interventional mental health services through its NeuroStar TMS technology.

In addition to revenue growth, Neuronetics reported an adjusted EBITDA of $1.9 million, a stark contrast to the $(4.7) million loss recorded in the same quarter of the previous year. The company also narrowed its net loss to $1.6 million from $9.4 million in Q3 2025, indicating improved operational efficiency and cost management.

Neuronetics, based in Malvern, Pennsylvania, is a leader in the surgical and medical instruments sector, specifically focusing on mental health treatments. The company trades on the Nasdaq under the ticker STIM and has been recognized for its innovative approach to treatment through its NeuroStar Advanced Therapy System.

The filing, submitted on November 4, 2026, included a press release detailing these financial results and a presentation for investors, which may shape investor perceptions and market strategies moving forward. The results reflect Neuronetics' commitment to enhancing its operational capabilities and expanding its service offerings.

Looking ahead, Neuronetics is expected to continue focusing on its growth strategy, particularly through its Greenbrook network. The company’s ability to maintain its momentum in revenue growth will be crucial as it navigates the competitive landscape of the surgical and medical instruments industry.

Details were not available in the SEC filing regarding future plans or specific upcoming initiatives, but the positive financial results suggest that Neuronetics is well-positioned to capitalize on its recent successes.

This financial update not only impacts Neuronetics but also sets a benchmark for competitors in the industry, who may need to adapt their strategies in response to the company's growing market presence.